First Annual Meeting
BioCrossroads
David Johnson, President and CEO
BioCrossroads
Indiana CTSI Annual Meeting
January 7-8, 2009
Indiana is a national leader in the life sciences, including a strength
in medical devices and equipment
•
Indiana is one of only three states (California and North Carolina, plus Puerto Rico)
to have specialized bioscience employment in three of four niche subsectors –
Drugs and Pharmaceuticals, Medical Devices and Equipment, and Agricultural
Feedstock and Chemicals (BIO/Battelle 2008)
•
Warsaw, Indiana is home to nearly half ($8 billion) of the nation’s orthopedic
device industry with over 20 major orthopedics device design, production and
manufacturing companies
•
Indiana is also a leader in cardiovascular and other medical devices with
companies, including Cook Group (the world’s largest private cardiovascular device
company), Boston Scientific, Roche Diagnostics, Beckman Coulter, and Hologic
•
Indiana has gained bioscience jobs at twice the nation’s average (BIO/Battelle)
Indiana’s life sciences leaders (and workforce)
Warsaw
• Zimmer (2,500)
• DePuy (1,200)
Lafayette
• Biomet (1,400)
•Eli Lilly and Company (800)
Indianapolis
•Purdue University
•Beckman Coulter (280)
•Purdue Research Park
•Covance (1,000)
Terre Haute
•Dow AgroSciences (1,000)
•Eli Lilly and Company
(200)
•Eli Lilly and Company (12,000)
•Hologic (200)
•Rose-Hulman
Institute of
Bloomington
Technology
•Medco (1,300)
•Roche Diagnostics (2,700)
• Indiana University
•WellPoint (4,500)
•Baxter Biopharma
Solutions (825)
Seymour/Spencer
•Cook Group
(2,200)
•Boston Scientific (800)
Evansville
•Cook Urology (400)
•Bristol Myers Squibb (300)
• UCB Group (360)
•Covance (200)
•Mead Johnson (1500)
www.biocrossroads.com
What is BioCrossroads?
BioCrossroads is Indiana’s initiative to build on our life sciences strengths
WE INVEST:
WE CONNECT:
By launching and
investing in new life
sciences enterprises
By partnering with
Indiana’s life sciences
research institutions,
corporations,
philanthropic
organizations and state
government to build new
opportunities
WE EDUCATE:
WE SPREAD THE WORD:
By expanding science
and math education in
grades K-12 and
higher learning
institutions
By marketing Indiana’s
life sciences industry
http://www.indianactsi.org
How BioCrossroads Works
WE CONNECT by creating new life sciences
enterprises:
–
IHIE – Indiana Health Information Exchange, Inc. a non-profit
corporation advancing a national model for the secure sharing of
clinical information among healthcare patients, providers and other
healthcare entities.
–
Mergetics – a new for-profit corporation that will market and
implement clinical messaging and clinical quality solutions to
communities beyond Indiana’s borders
–
Fairbanks Institute for Healthy Communities– an enterprise utilizing
Indiana’s vast clinical resources to gather comprehensive patient
clinical and biological information for the prediction, prevention and
treatment of disease.
–
BioCrossroadsLINX –advancing Indiana's strengths in drug
development and manufacturing through educational and workforce
development programs and regional collaborations.
–
Datalys Center for Sports Injury Research and Prevention- a national
non-profit organization providing research and surveillance services
to sports and health organizations
Mergetics
How BioCrossroads Works
WE INVEST by forming venture funds to provide money for
new companies:
– Indiana Future Fund I – a $73 million fund-of-funds
(managed by Credit Suisse)
– Indiana Seed Fund I – a $6 million “pre-venture” fund
(managed by BioCrossroads)
– More investment funds coming in 2009
“I do great science but I didn’t know how to
structure a business...They were such
wonderful guides.” - Linda H. Malkas, CSKeys Co-founder and Indiana Seed Fund
recipient
How does BioCrossroads measure success?
By putting Indiana on the national map of life
sciences, biotechnology, medical device and
health care information centers.
www.biocrossroads.com
http://www.indianactsi.org
We start with a good map today…
www.biocrossroads.com
Indianapolis - 9th largest life sciences employment sector in the U.S.
Metro areas with the largest total employment levels (greater than 10,000) in the BioSciences by Major
Subsector Composition, 2004. Battelle “Growing the Nation’s Bioscience Sector: A Regional Perspective” 2007
www.biocrossroads.com
And now we have other national distinctions:
www.biocrossroads.com
Indiana is a national laboratory for health care reform
•
•
“Health care modernization” will be driven by better clinical information, and
Indiana is a national leader in this field
Indiana has nationally-recognized health information assets
– Regenstrief Institute – an internationally recognized clinical informatics and health
care research organization
– The Indiana Health Information Exchange regional health information network,
started by BioCrossroads, is “the most advanced in the United States” (Health Affairs,
Aug. 2007)
– Mergetics, a newly formed spin-off from IHIE, will connect Indiana’s health information
exchange model to new communities outside the state
– The NIH has recently made a Clinical and Translational Science Award to the IU School
of Medicine that will include a new “health economics” platform for enhanced health
outcomes, driven by the Regenstrief Institute and HealthCore, a health care subsidiary
of WellPoint
Indiana is a national success story for public-private partnerships
•
Clinical and Translational Science Institute (CTSI) – IUSM, Purdue and Notre Dame
–
$25 million grant from the NIH to fund collaborative university-industry translational
research programs
– Federal dollars will be supplemented by another nearly $60 million from IU and Purdue,
the State of Indiana, Eli Lilly and Co. and the Richard M. Fairbanks Foundation, Inc.
•
The State of Indiana’s important and supporting role within the life sciences sector
– Established 21st Century Fund through the Indiana Economic Development Corporation
(half of the 62 funded are life sciences companies)
– Aligns economic development efforts with life sciences strengths (7,000 new life
sciences jobs; $700 million company investments since 2005)
– Department of Workforce Development has targeted specific training programs to
advance Indiana’s biotechnology and orthopedics workforce
www.biocrossroads.com
Indiana is a national leader in economic cluster development
•
Central Indiana – from West Lafayette (Purdue University) to Indianapolis to
Bloomington (Indiana University)
– High concentration of both established corporate headquarters and startup/entrepreneurial organizations
– Central Indiana is home to a “$13.6 billion global life science hub” (Standard & Poor’s
2008)
•
Biopharmaceutical and medical device contract services
– More than 50 biopharma contract development and manufacturing service providers
(CROs) are located throughout Indiana, with many medical device suppliers located
within the state as well
•
Warsaw, IN – Orthopedics Capital of the World
– Warsaw companies account for ½ of the U.S. orthopedics industry annual revenues ($8
billion)
– Headquarters for BioMet, DePuy, and Zimmer, supported by other major orthopedic
companies, including Symmetry, Paragon and more than 20 others
– BioCrossroads is working on a collaboration industry with IUSM, Purdue and Notre
Dame for orthopedics research and innovation
Indiana is a national model for inter-regional collaborations
•
In a unique partnership, Indiana and San Diego working together to bolster
complementary strengths in biotechnology innovation: Indiana – biopharma
development and manufacturing; and San Diego – biotech discovery
•
BioCrossroads is collaborating with CONNECT, the San Diego region's nationally
renowned organization of businesses and universities building 21st century
companies, as well as BIOCOM, the nation’s largest regional biotechnology
association headquartered in San Diego
•
BioCrossroadsLINX is working with San Diego and Indiana research institutions to
find additional areas of collaboration within biotech discovery and development
Indiana is a national destination for venture investment
•
In 2004, Indiana had no local VC community for life sciences investments and
attracted no national venture capital firms
•
Today, there are at least 18 angel, seed and venture capital funds actively looking
for deals in Indiana, including 7 now organized and based here and focused on
Indiana’s life sciences opportunities
•
2007 saw $136.6 million in venture capital invested in Indiana companies; a record
year and triple the amount invested in 2002
•
Indiana’s model for VC success is a unique, market-driven approach, bringing
together a diverse group of institutional investors focused first and foremost on
return
The Indiana CTSI will play a pivotal role in the success of all 4 of our major
BioCrossroads Initiatives in 2009:
• Catalyzing Indiana’s national strengths in healthcare information, health
outcomes and “healthcare modernization” (Mergetics/IHIE)
• Accelerating translational research to inspire the growth of new
companies for capitalizing by our seed and venture funds (Indiana Future
Fund/Indiana Seed Fund)
• Developing the research infrastructure to secure Indiana’s place as an
international center for biopharmaceutical development and
manufacturing (BioCrossroadsLINX)
• Advancing collaborative, statewide innovation to support Indiana’s
unmatched capabilities in orthopedics (Orthopedics Initiative)